Extended-release oral drug delivery

Extended-Release Oral Drug Delivery Technologies Monolithic Matrix Systems... 

S.B. Tiwari, and A.R. Siahboomi, Extended-release oral drug delivery technologies Monolithic matrix systems, in KK. Jain, ed.. Drug Delivery Systems, Humana Press, Totowa, NJ, 217-243, 2004. 

Expandable DFs are oral delivery devices that increase their size considerably after ingestion the extended dimensions are aimed to be retained in the stomach and consequently increase their GRT. These DFs are planned to release their drug content in the stomach and be subsequently evacuated owing to the decrease of their dimension and rigidity. 

Considerable advances have occurred in DDS within the past decade. Extended release, controlled release, and once-a-day medications are available for several commonly used drugs. Global vaccine programs are close to becoming a reality with the use of oral, transmucosal, transcutaneous, and needle-less vaccination. Considerable advances have been made in gene therapy and delivery of protein therapeutics. Many improvements in cancer treatment can be attributed to novel drug delivery technologies. 

Drug delivery systems of once-daily products (Concerta, Metadate CD, Ritalin LA, Adderall XR) provide 8 to 12 hours of symptom control. Concerta uses an oral osmotic (OROS) controlled-release delivery system, while other preparations use combinations of immediate-release or extended-release beads containing drug. Concerta is a nondeformable tablet and it should not be given to children with gastrointestinal narrowing due to the risk of obstruction. Older wax-matrix sustained-release products (e.g., Ritalin SR)... 

---